source
- AstraZeneca invests $2 billion for stake in Summit Therapeutics to back its cancer drugAstraZeneca announced on Monday that it will invest $2 billion to acquire a minority equity stake in Summit Therapeutics. The investment gives AstraZeneca a slice of the biotech as the companies mo…
- Mirum reports Phase 3 success for its acquired hepatitis D therapyMirum Pharmaceuticals announced that its recently acquired chronic hepatitis delta drug met its primary endpoint in a Phase 3 trial. The study tested a once-weekly 300 mg injection, and more than…